rituximab
biogen,roche
[]
avouac et al. maintaining complete b cell depletion assoc rtx efficacy in ctd-ild. % with fvc improvement - 67% vs 50% for b cell depletion 1 year, 89% vs 50% b cell depletion last infusion. #acr22 abstr#1527 
Rheumatologist @stjamesdublin , Associate Professor @tcddublin , Acute Medicine, Vasculitis, ILD, Retired @Emeunet Executive Committee member, @rheum_covid CASC